Acorda Therapeutics Inc (NASDAQ:ACOR) has received a consensus recommendation of “Hold” from the twelve analysts that are covering the stock, MarketBeat reports. Four analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $10.21.
Several brokerages have recently commented on ACOR. HC Wainwright reissued a “hold” rating and set a $6.00 price target on shares of Acorda Therapeutics in a research note on Tuesday, November 5th. ValuEngine raised Acorda Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. lowered Acorda Therapeutics from a “neutral” rating to an “underweight” rating and set a $1.40 price target on the stock. in a research note on Thursday, October 24th.
Shares of NASDAQ:ACOR traded down $0.23 during trading on Wednesday, hitting $1.83. 1,953,501 shares of the stock were exchanged, compared to its average volume of 1,249,384. The company has a fifty day moving average price of $2.03 and a two-hundred day moving average price of $4.74. The company has a market cap of $87.90 million, a PE ratio of 1.01 and a beta of 1.15. The company has a current ratio of 3.42, a quick ratio of 3.12 and a debt-to-equity ratio of 1.33. Acorda Therapeutics has a 12-month low of $1.49 and a 12-month high of $19.32.
Several institutional investors have recently modified their holdings of the stock. Advisory Services Network LLC raised its position in shares of Acorda Therapeutics by 9.6% during the 2nd quarter. Advisory Services Network LLC now owns 40,000 shares of the biopharmaceutical company’s stock worth $307,000 after purchasing an additional 3,500 shares during the last quarter. Aperio Group LLC raised its position in shares of Acorda Therapeutics by 39.0% during the 2nd quarter. Aperio Group LLC now owns 14,124 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 3,961 shares during the last quarter. KBC Group NV acquired a new position in shares of Acorda Therapeutics during the 2nd quarter worth approximately $31,000. Comerica Bank raised its position in shares of Acorda Therapeutics by 22.5% during the 3rd quarter. Comerica Bank now owns 44,988 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 8,268 shares during the last quarter. Finally, Gabelli Funds LLC acquired a new position in shares of Acorda Therapeutics during the 2nd quarter worth approximately $80,000.
About Acorda Therapeutics
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
Recommended Story: What is a front-end load?
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.